Gadoterate meglumine is named as a drug or biological intervention in 2 clinical trials in our USA trial register, 2 of which are recruiting. The lead sponsor is Guerbet. Registered phases: Phase 4 and Phase 3. Conditions studied include Motor Function; Cognitive Function; Contrast Media.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT04373564 | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years (ClinicalTrials.gov ↗) Motor Function, Cognitive Function, Contrast Media |
Phase 4 | Recruiting |
| NCT07348640 | Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease (ClinicalTrials.gov ↗) Steno-occlusive Disease |
Phase 3 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Motor Function | 1 |
| Cognitive Function | 1 |
| Contrast Media | 1 |
| Steno-occlusive Disease | 1 |
| Lead sponsor | Trials |
|---|---|
| Guerbet | 2 |
| Register | Gadoterate meglumine trials |
|---|---|
| Clinical trials in USA | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Gadoterate meglumine works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Gadoterate meglumine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.